Abstract
Background: Sleep disorders, particularly Obstructive Sleep Apnea (OSA) and Insomnia Disorder (ID), are associated with systemic inflammation. However, the diagnostic and monitoring utility of specific cytokine profiles remains unclear.
Objective: To identify distinct serum cytokine signatures in OSA and ID compared to healthy controls (HC) at baseline and to evaluate longitudinal changes in these biomarkers following standard treatment.
Methods: In this pilot study, 75 cases (25 OSA, 25 ID, 25 HC) were enrolled. Serum levels of IL-6, TNF-α, IL-1β, IL-10, and CRP were measured at baseline using multiplex immunoassay. All patients underwent polysomnography and clinical assessment. The OSA and ID cohorts were re-evaluated after 3 months of treatment (CPAP for OSA, CBT-I for ID) with repeat cytokine analysis.
Results: At baseline, the OSA group showed significantly elevated levels of IL-6 (p<0.001), TNF-α (p=0.003), and CRP (p<0.001) compared to HC. The ID group had elevated IL-6 (p=0.01) and IL-1β (p=0.02) but not CRP. A combined panel of IL-6, TNF-α, and IL-1β differentiated OSA from ID with an AUC of 0.87 (95% CI: 0.78-0.96). Longitudinally, CPAP therapy in adherent patients (>4 hrs/night) led to a significant reduction in IL-6 (p=0.004) and CRP (p=0.008), correlating with apnea-hypopnea index (AHI) improvement (r=0.65, p=0.002). CBT-I in ID led to a reduction in IL-1β (p=0.03), which correlated with improved sleep efficiency (r=-0.52, p=0.02).
Conclusion: This pilot study identifies disorder-specific inflammatory profiles in OSA and ID. Serum IL-6 and CRP are promising biomarkers for OSA severity and treatment response, while IL-1β may be salient to insomnia pathophysiology. These findings support the role of cytokines as complementary objective tools for diagnosis and monitoring in sleep medicine.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.